Long-Acting Reversible Contraception Highly Acceptable

This article originally appeared here.
Share this content:
Long-Acting Reversible Contraception Highly Acceptable
Long-Acting Reversible Contraception Highly Acceptable

WEDNESDAY, Sept. 28, 2016 (HealthDay News) -- Long-acting reversible contraception (LARC) is highly acceptable even among women who present to initiate short-acting reversible contraception (SARC), according to a study published online Sept. 19 in the American Journal of Obstetrics & Gynecology.

David Hubacher, Ph.D., from FHI 360 in Raleigh, N.C., and colleagues conducted a partially randomized patient preference trial involving 916 women aged 18 to 29 years who were seeking a short-acting contraceptive method. Forty-three percent of participants were randomized to either LARC or SARC. The remaining 57 percent of women who declined randomization but agreed to follow-up were observed after choosing their preferred method.

The researchers found that the probability of continuation at 12 months was 63.3, 53.0, and 77.8 percent for the preference SARC, randomized SARC, and randomized LARC, respectively (P < 0.001 in the comparison involving randomized groups). The probability of 12-month cumulative pregnancy was 6.4, 7.7, and 0.7 percent, respectively (P = 0.01 comparing randomized groups). The proportion who were happy/neutral with their initial method was 78 percent for randomized LARC users versus 89 percent for randomized SARC users (P < 0.05). All groups were equally happy/neutral among method continuers at 12 months (>90 percent).

"Even in a typical population of women who presented to initiate or continue short-acting reversible contraception, long-acting reversible contraception proved highly acceptable," the authors write.

Several authors disclosed financial ties to Bayer, Teva, and Merck, all of which contributed funding to the study.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »